Amyloid brain PET imaging

Author(s): Nick Gulliver, Dr Nicola Mulholland, Dr Gill Vivian

Hospital: King's College Hospital NHS Foundation Trust

Reference: RAD Magazine, 43, 506, 15-17


Brain positron emission tomography (PET) has also been used over many years to diagnose neurodegenerative diseases, and has advantages over MRI due to its higher sensitivity to detect pathologies at a molecular level. While 18F-fluorodeoxyglucose (FDG) PETCT is an established imaging technique for assisting in the differential diagnosis of Alzheimer’s disease (AD) and other forms of dementia, PETCT imaging using beta-amyloid plaque avid tracers has only recently come into clinical use in the UK, having been a subject of intensive research and development in recent years. This review briefly describes the principles and practice of amyloid brain PET imaging, including image acquisition, image interpretation and future developments.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more